Controversies in the Treatment of Lung Cancer

12th International Symposium on Special Aspects of Radiotherapy, Berlin, October 2008

Editor(s): Heide J. (Berlin) 
Schmittel A. (Berlin) 
Kaiser D. (Berlin) 
Hinkelbein W. (Berlin) 
Table of Contents
Vol. 42, No. , 2010
Section title: NSCLC: Stage III Disease
Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds): Controversies in the Treatment of Lung Cancer. Front Radiat Ther Oncol. Basel, Karger, 2010, vol 42, pp 115–121

Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer

Hillinger S. · Weder W.
Division of Thoracic Surgery, University Hospital, Zürich, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Stage III includes a large variety of clinical situations from chest wall invasion together with intralobar lymph node metastasis to any size of a lung cancer in combination with mediastinal lymph node involvement (N2/N3). Furthermore, the prognosis of patients with lymph node metastasis depends largely on the extent of the disease, which may range from micro-metastasis occasionally found during surgery to bulky and/or multilevel involvement of the mediastinum or extracapsular infiltration. Not surprising the optimal treatment including the role of surgery for stage IIIA (N2) and stage IIIB (T4/N3) non-small cell lung cancer is discussed controversially. Adequate analysis of the clinical stage is key to select the best treatment. In general, patients benefit from surgery, when a radical resection can be achieved with a low morbidity and mortality. A multidisciplinary approach is indicated in most patients, which present with stage III disease at diagnosis. Preferentially patients should be treated in study protocols whenever they are available. Radical surgery including chest wall resection may result in a 5-year survival rate of up to 50% in T3N1 disease. Adjuvant chemotherapy is recommended and radiotherapy is reserved for cases with unclear resection margins. Clinical trials of preoperatively proven N2 patients could show a better outcome when downstaging is achieved after neoadjuvant chemo- or chemoradiotherapy prior to surgery. Patients who may need a pneumonectomy should be selected with caution since some centers experience a high perioperative mortality rate. If unforeseen N2 disease is found during surgery, an adjuvant therapy is recommended. Patients with T4 tumors (infiltration of great vessels, trachea, esophagus, vertebral bodies, etc.) show an increasing 5-year survival from 15 to 35% after radical resection with acceptable perioperative mortality if treated in experienced centers. In stage III non-small cell lung cancer, surgery should be performed within a multimodality approach. Surgery should be recommended when resection is radical including systematic lymph node dissection and mortality and morbidity are low.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Lababede O, Meziane MA, Rice TW: TNM staging of lung cancer: a quick reference chart. Chest 1999;115:233-235
  2. Burkhart HM, Allen MS, Nichols FC, 3rd, Des-champs C, Miller DL, Trastek VF, Pairolero PC: Results of en bloc resection for bronchogenic carcinoma with chest wall invasion. J Thorac Cardiovasc Surg 2002;123:670-675
  3. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D: Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007;25:313-318
  4. Marra A, Eberhardt W, Pöttgen C, Theegarten D, Korfee S, Gauler T, Stuschke M, Stamatis G: Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour. Eur Respir J 2007;29:117-126
  5. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le Chevalier T: Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989
  6. Robinson LA, Ruckdeschel JC, Wagner H, Jr, Stevens CW: American College of Chest Physicians: Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines. 2Chest 2007;132:(3 suppl)243S-265S
  7. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G: European Organisation for Research and Treatment of Cancer-Lung Cancer Group: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450
  8. Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC: North American Lung Cancer Intergroup: Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs. CT/ RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005;23:624s
  9. Siegenthaler MP, Pisters KM, Merriman KW, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Smythe WR, Putnam JB, Jr: Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 2001;71:1105-1111
  10. Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-1759
  11. Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, Hausner P, Krasna M: Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004;78:1200-1205discussion1206
  12. Kaya AO, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M, Yildiz R, Ozturk B, Yaman E, Kalender ME, Orhan O, Yamac D, Uner A: Anatolian Society of Medical Oncology (ASMO): Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Med Oncol 2009 [Epub ahead of print]
  13. Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM: Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009;35:718-723
  14. Ma Z, Dong A, Fan J, Cheng H: Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis. Eur J Cardiothorac Surg 2007;32:20-28
  15. Grunenwald DH: Surgery for advanced stage lung cancer. Semin Surg Oncol 2000;18:137-142
  16. Farjah F, Wood DE, Varghese TK, Jr, Symons RG, Flum DR: Trends in the operative management and outcomes of T4 lung cancer. Ann Thorac Surg 2008;86:368-374
  17. Rice TW, Blackstone EH: Radical resections for T4 lung cancer. Surg Clin North Am 2002;82:573-587
  18. Grunenwald DH, Mazel C, Girard P, Veronesi G, Spaggiari L, Gossot D, Debrosse D, Caliandro R, Le Guillou JL, Le Chevalier T: Radical en bloc resection for lung cancer invading the spine. J Thorac Cardiovasc Surg 2002;123:271-279
  19. Naruke T: Significance of lymph node metastases in lung cancer. Semin Thorac Cardiovasc Surg 1993;5:210-218
  20. Albain KS: Induction chemotherapy with/without radiation followed by surgery in stage III non-small-cell lung cancer. Oncology (Williston Park) 1997;11:(9 suppl 9)51-57
  21. Grunenwald DH, André F, Le Péchoux C, Girard P, Lamer C, Laplanche A, Tarayre M, Arriagada R, Le Chevalier T: Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:796-802
  22. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00